Scholarlink

<p>Remogliflozin etabonate, a selective sodium-dependent glucose transporter 2 antagonist, reduces glucose levels in type 2 diabetes by inhibiting renal glucose reabsorption. This study developed a bioanalytical reverse-phase high-performance liquid chromatography method for quantifying remogliflozin etabonate in human plasma. The method utilized a Kromasil C18 column (250&#xa0;mm × 4.6&#xa0;mm; 5&#xa0;μm), with detection at 228&#xa0;nm and selexipag as the internal standard. The mobile phase comprised acetonitrile and 0.1% orthophosphoric acid in water (70:30, v/v), and separation was performed in an isocratic mode with a flow rate of 1.0 mL/min. The analyte was isolated from the spiked plasma matrix using the protein precipitation technique. Remogliflozin etabonate and selexipag eluted at 4.08 and 9.06&#xa0;min, respectively. The method demonstrated satisfactory linearity (1.50–60&#xa0;µg/mL, r² = 0.9998) and high extraction recovery (97.46%–99.21%). Stability studies confirmed accuracy within ± 15%, %CV &lt; 6%, and no significant degradation of remogliflozin etabonate. The developed method can be applied for routine analysis of remogliflozin etabonate in spiked human plasma samples.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A validated RP-HPLC bioanalytical method for the quantification of remogliflozin etabonate in spiked human plasma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月8日

查看全文
  • Pravin Rangnath Dighe,
  • Manoj Ramesh Kumbhare

摘要

Remogliflozin etabonate, a selective sodium-dependent glucose transporter 2 antagonist, reduces glucose levels in type 2 diabetes by inhibiting renal glucose reabsorption. This study developed a bioanalytical reverse-phase high-performance liquid chromatography method for quantifying remogliflozin etabonate in human plasma. The method utilized a Kromasil C18 column (250 mm × 4.6 mm; 5 μm), with detection at 228 nm and selexipag as the internal standard. The mobile phase comprised acetonitrile and 0.1% orthophosphoric acid in water (70:30, v/v), and separation was performed in an isocratic mode with a flow rate of 1.0 mL/min. The analyte was isolated from the spiked plasma matrix using the protein precipitation technique. Remogliflozin etabonate and selexipag eluted at 4.08 and 9.06 min, respectively. The method demonstrated satisfactory linearity (1.50–60 µg/mL, r² = 0.9998) and high extraction recovery (97.46%–99.21%). Stability studies confirmed accuracy within ± 15%, %CV < 6%, and no significant degradation of remogliflozin etabonate. The developed method can be applied for routine analysis of remogliflozin etabonate in spiked human plasma samples.

Graphical Abstract